|
|
| AASLD |
American Association for the Study
|
HIV |
Human immunodeficiency virus |
| of LiverDisease |
INR |
International normalized ratio |
| ACEI |
Angiotensin-converting enzyme inhibitor(s) |
IVDU |
Intravenous drug user |
| ADA |
American Diabetes Association |
KDIGO |
Kidney Disease: Improving Global Outcomes |
| ALT |
Alanine aminotransferase |
KDOQI |
Kidney Disease Outcomes Quality Initiative |
| ARB |
Angiotensin receptor blocker(s) |
MGN |
Membranous glomerulonephritis |
| AST |
Aspartate aminotransferase |
MPGN |
Membranoproliferative |
| AUC |
Area under the curve |
NAT |
Nucleic acid test(ing) |
| CARI |
Caring for Australians with Renal Impairment |
NHANES III |
Third National Health and Nutrition Survey |
| CDC |
Centers for Disease Control and Prevention |
NIH |
National Institutes of Health |
| CKD |
Chronic kidney disease |
NODAT |
New-onset diabetes after transplantation |
| CSN |
Canadian Society of Nephrology |
PCR |
Polymerase chain reaction |
| DOPPS |
Dialysis Outcomes and Practice Patterns Study |
RCT |
Randomized controlled trial |
| EBPG |
European Best Practice Guidelines |
ROC |
Receiver operating characteristics |
| EDTA |
Ethylenediaminetetraacetic acid |
RR |
Relative risk |
| EIA |
Enzyme immunoassay |
SVR |
Sustained virologic response |
| GFR |
Glomerular filtration rate |
SQ |
Subcutaneous(ly) |
| GN |
Glomerulonephritis |
TLR-3 |
TOLL-like receptor 3 |
| GRADE |
Grades of Recommendation, Assessment, |
TMA |
Transcription-mediated amplification |
| Development and Evaluation |
UK-RA |
United Kingdom Renal Association |
| HBV |
Hepatitis B virus |
USRDS |
United States Renal Data System |
| HCV |
Hepatitis C virus |
WHO |
World Health Organization |